EUVIMEDEUVIMED entdecken
Systematische Übersicht

Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review

Kaijie Yao, Hao Feng, Ying Chen, Yun Bao, Mengxia Yan, Wen Li, Bin Wu

Clinical Drug Investigation · 2025-10 · 45 (10) · 681-700

DOI: 10.1007/s40261-025-01477-0 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Drug Investigation, online erschienen am 17.09.2025. Verfasst von Kaijie Yao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Antiviral Agents, Drug Development, Hepatitis B, Hepatitis B virus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Chronic hepatitis B virus infection remains a Major global public health challenge, affecting over 254 million individuals and causing substantial mortality owing to the limited curative potential of current therapies. This horizon scanning review aims to comprehensively analyze emerging trends and future directions in novel anti-hepatitis B virus therapeutic development, evaluating their progress and potential to achieve functional or complete cures. METHODS: We conducted a systematic horizon scanning review from January 2020 to June 2025, searching databases (PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure [CNKI], and WanFang), clinical trial registries (ClinicalTrials.gov, EU Clinical Trials Register, World Health Organization International Clinical Trials Registry, Chinese Clinical Trial Registry, and chinadrugtrials.org), hepatology conference abstracts (American Association for the Study of Liver Diseases, European Association for the Study of the Liver), and pharmaceutical company websites. Inclusion criteria focused on studies detailing novel anti-hepatitis B virus treatments, with data extracted on category, target, clinical phase, and discontinuation reasons. RESULTS: Our analysis identified 161 unique anti-hepatitis B virus treatments: 75 in clinical trials, 34 in preclinical development, and 52 discontinued post-clinical trials because of safety or insufficient efficacy. The pipeline reveals a diversification of targets, with capsid assembly modulators, therapeutic vaccines, and monoclonal antibodies being most prevalent. Three therapies representing novel mechanisms have reached phase III-bepirovirsen (an antisense oligonucleotide), canocapavir (a capsid assembly modulator), and εPA-44 (a therapeutic vaccine), illustrating diversification of late-stage pipelines; however, 6-month off-treatment endpoints should be interpreted cautiously across modalities until durability is established. CONCLUSIONS: The robust and diverse pipeline of novel anti-hepatitis B virus treatments offers promise for improving functional cure rates, but definitive conclusions await longer off-treatment follow-up and durability data. Continued research, rational combination strategies, and global collaboration are crucial to overcome challenges and ensure equitable access to these transformative therapies worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDrug DevelopmentHepatitis BHepatitis B virusHepatitis B, ChronicHumans

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China.
  • Institute of Clinical Research and Evidence Based Medicine, Gansu Provincial Hospital, Lanzhou, Gansu, China.
  • Department of Pharmacy, Ningbo Hangzhou Bay Hospital, Ningbo, Zhejiang, China.
  • Department of Pharmacy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yao, K., Feng, H., Chen, Y., Bao, Y., Yan, M., Li, W., & Wu, B. (2025). Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review. Clinical Drug Investigation, 45(10), 681-700. https://doi.org/10.1007/s40261-025-01477-0

Vancouver

Yao K, Feng H, Chen Y, Bao Y, Yan M, Li W, et al. Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review. Clinical Drug Investigation. 2025;45(10):681-700. doi:10.1007/s40261-025-01477-0

BibTeX
@article{Yao2025,
  author = {Yao, Kaijie and Feng, Hao and Chen, Ying and Bao, Yun and Yan, Mengxia and Li, Wen and Wu, Bin},
  title = {Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review},
  journal = {Clinical Drug Investigation},
  year = {2025},
  volume = {45},
  number = {10},
  pages = {681--700},
  doi = {10.1007/s40261-025-01477-0}
}
Kostenlos starten →